CD59 anticorps
-
- Antigène Voir toutes CD59 Anticorps
- CD59
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp CD59 est non-conjugé
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), ELISA
- Purification
- Affinity purification
- Immunogène
- Synthetic peptide of human CD59
- Isotype
- IgG
- Top Product
- Discover our top product CD59 Anticorps primaire
-
-
- Indications d'application
- WB 1:500-1:2000, IHC 1:100-1:300
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 0.5 mg/mL
- Buffer
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
- Agent conservateur
- Sodium azide
- Conseil sur la manipulation
- Avoid freeze / thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C. Avoid freeze / thaw cycles.
-
- Antigène
- CD59
- Autre désignation
- CD59 (CD59 Produits)
- Synonymes
- anticorps 16.3A5, anticorps 1F5, anticorps EJ16, anticorps EJ30, anticorps EL32, anticorps G344, anticorps HRF-20, anticorps HRF20, anticorps MAC-IP, anticorps MACIF, anticorps MEM43, anticorps MIC11, anticorps MIN1, anticorps MIN2, anticorps MIN3, anticorps MIRL, anticorps MSK21, anticorps p18-20, anticorps Cd59a, anticorps Cd59b, anticorps MACIP, anticorps CD59 molecule (CD59 blood group), anticorps CD59 molecule, anticorps CD59, anticorps Cd59
- Sujet
- This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction.
- Poids moléculaire
- Calculated MW: 14 kDa
- NCBI Accession
- NP_000602
- Pathways
- Système du Complément
-